the offices of
Crucell at Archimedesweg 4-6, 2333 CN Leiden, the Netherlands; at the offices
of the Dutch Settlement Agent, ING Bank N.V., Bijlmerdreef 888 1102 MG
Amsterdam, the Netherlands (Attention: Sjoukje Hollander/Remko Los), telephone:
+ 31 20 563 6546 / + 31 20 563 6619, email: iss.pas@ing.nl); and at the offices
of the U.S. Settlement Agent, Computershare Trust Company, N.A., 250 Royall
Street, Canton, MA 02021.
About
Crucell
Crucell
N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2010 alone, Crucell distributed more than 105 million
vaccine doses in more than 100 countries around the world. Crucell is one of
the major suppliers of vaccines to UNICEF and the developing world. Crucell was
the first manufacturer to launch a fully-liquid pentavalent vaccine. Called
Quinvaxem®, this innovative combination vaccine protects against five important
childhood diseases. Over 180 million doses have been sold since its launch in
2006 in more than 50 GAVI countries. With this innovation, Crucell has become a
major partner in protecting children in developing countries. Other products in
Crucell’s core portfolio include a vaccine against hepatitis B and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the
only aluminum-free hepatitis A vaccine on the market. Crucell has a broad
development pipeline, with several product candidates based on its unique
PER.C6® production technology. Crucell licenses its PER.C6® technology and
other technologies to the biopharmaceutical industry. Important partners and
licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis,
Novartis, Pfizer/Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered
in Leiden, the Netherlands, with offices in China, Indonesia, Italy, Korea,
Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Crucell employs
over 1300 people. For more information, please visit www.crucell.com.
About
Johnson & Johnson
Caring for the world, one person at a
time…inspires and unites the people of Johnson & Johnson. We embrace
research and science – bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately 114,000
employees at more than 250 Johnson & Johnson companies work with partners
in health care to touch the lives of over a billion people every day throughout
the world.
Forward-looking
statements
(This press release contains
“forward-looking statements”. All statements other than statements of
historical fact are statements that could be deemed forward-looking statements.
These statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could vary materially from Johnson & Johnson’s
and Crucell’s expectations and projections. Risks and uncertainties include
general industry conditions and competition; general domestic and international
economic conditions, such as interest rate